Terms: = Breast cancer AND ERCC2, TTD, 2068, ENSG00000104884, COFS2, P18074, MGC102762, XPD, MGC126219, MGC126218, EM9 AND Treatment
52 results:
1. Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study.
Schmid P; Lipatov O; Im SA; Goncalves A; Muñoz-Couselo E; Lee KS; Tamura K; Testa L; Witzel I; Ohtani S; Turner N; Zambelli S; Harbeck N; Andre F; Dent R; Mejia JA; Zhou X; Haiderali A; Nguyen AM; Cortes J; Winer EP
Eur J Cancer; 2023 Dec; 195():113393. PubMed ID: 37976633
[TBL] [Abstract] [Full Text] [Related]
2. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels the heterogeneity of cancer-associated fibroblasts in TNBC.
Wu X; Lu W; Zhang W; Zhang D; Mei H; Zhang M; Cui Y; Zhuo Z
Aging (Albany NY); 2023 Nov; 15(21):12674-12697. PubMed ID: 37963845
[TBL] [Abstract] [Full Text] [Related]
3. The Curcumin Analog PAC Is a Potential Solution for the treatment of Triple-Negative breast cancer by Modulating the Gene Expression of DNA Repair Pathways.
Almalki E; Al-Amri A; Alrashed R; Al-Zharani M; Semlali A
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298600
[TBL] [Abstract] [Full Text] [Related]
4. Optimal treatment of Hormone Receptor-positive Advanced breast cancer Patients With Palbociclib.
Morita M; Ooe A; Ishii W; Watanabe A; Matsui C; Okuyama Y; Kitano S; Kato C; Onishi M; Sakaguchi K; Naoi Y
Anticancer Res; 2023 Jun; 43(6):2783-2789. PubMed ID: 37247903
[TBL] [Abstract] [Full Text] [Related]
5. Genetic variability of oxidative stress and DNA repair genes associated with pre-treatment cancer-related fatigue in women with breast cancer.
Davis T; Koleck T; Conway A; Bender C; Conley Y
Support Care Cancer; 2023 May; 31(6):345. PubMed ID: 37212918
[TBL] [Abstract] [Full Text] [Related]
6. PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant.
Degenhardt T; Fasching PA; Lüftner D; Müller V; Thomssen C; Schem C; Witzel I; Decker T; Tesch H; Kümmel S; Uleer C; Wuerstlein R; Hoffmann O; Warm M; Marschner N; Schinköthe T; Kates RE; Schumacher J; Otremba B; Zaiss M; Harbeck N; Schmidt M;
Trials; 2023 May; 24(1):338. PubMed ID: 37198674
[TBL] [Abstract] [Full Text] [Related]
7. The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer.
Hjorth CF; Damkier P; Stage TB; Feddersen S; Hamilton-Dutoit S; Ejlertsen B; Lash TL; Bøggild H; Sørensen HT; Cronin-Fenton D
Cancer Chemother Pharmacol; 2023 Feb; 91(2):157-165. PubMed ID: 36598552
[TBL] [Abstract] [Full Text] [Related]
8. Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent kinase 4 and 6 inhibitors: large-scale data analysis using a Japanese claims database.
Kawai M; Takada M; Nakayama T; Masuda N; Shiheido H; Cai Z; Huang YJ; Kawaguchi T; Tanizawa Y
Breast Cancer Res Treat; 2023 Jan; 197(2):435-447. PubMed ID: 36414795
[TBL] [Abstract] [Full Text] [Related]
9. APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative breast cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy.
Sammons S; Raskina K; Danziger N; Alder L; Schrock AB; Venstrom JM; Knutson KL; Thompson EA; McGregor K; Sokol E; Chumsri S
JCO Precis Oncol; 2022 Oct; 6():e2200149. PubMed ID: 36315915
[TBL] [Abstract] [Full Text] [Related]
10. Statin use in patients with hormone receptor-positive metastatic breast cancer treated with everolimus and exemestane.
Lee K; Noh E; Moon SJ; Joo YY; Kang EJ; Seo JH; Park IH
Cancer Med; 2023 Mar; 12(5):5461-5470. PubMed ID: 36263515
[TBL] [Abstract] [Full Text] [Related]
11. Utility values and its time to deterioration in breast cancer patients after diagnosis and during treatments.
Haidari RE; Anota A; Dabakuyo-Yonli TS; Guillemin F; Conroy T; Velten M; Jolly D; Causeret S; Cuisenier J; Graesslin O; Abbas LA; Nerich V
Qual Life Res; 2022 Oct; 31(10):3077-3085. PubMed ID: 35590124
[TBL] [Abstract] [Full Text] [Related]
12. Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) treatment in Patients with HER2-Positive Metastatic breast cancer: Updated Results of a Randomized, Double-Blind Study.
Li RK; Tokunaga E; Adamchuk H; Vladimirov V; Yanez E; Lee KS; Bondarenko I; Vana A; Hilton F; Ishikawa T; Tajima K; Lipatov O
BioDrugs; 2022 Jan; 36(1):55-69. PubMed ID: 35133617
[TBL] [Abstract] [Full Text] [Related]
13. [Mechanism of Xiaoyao San in treatment of depression,breast hyperplasia,and functional dyspepsia based on network pharmacology].
Wei FX; Liu HL; Fan YH; Li XQ; Zhao SJ; Qin XM; Liu XJ
Zhongguo Zhong Yao Za Zhi; 2021 Aug; 46(16):4230-4237. PubMed ID: 34467737
[TBL] [Abstract] [Full Text] [Related]
14. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
Kahan Z; Gil-Gil M; Ruiz-Borrego M; Carrasco E; Ciruelos E; Muñoz M; Bermejo B; Margeli M; Antón A; Casas M; Csöszi T; Murillo L; Morales S; Calvo L; Lang I; Alba E; de la Haba-Rodriguez J; Ramos M; López IÁ; Gal-Yam E; Garcia-Palomo A; Alvarez E; González-Santiago S; Rodríguez CA; Servitja S; Corsaro M; Rodrigálvarez G; Zielinski C; Martín M
Eur J Cancer; 2021 Oct; 156():70-82. PubMed ID: 34425406
[TBL] [Abstract] [Full Text] [Related]
15. Clinical and cost outcomes following genomics-informed treatment for advanced cancers.
Weymann D; Pollard S; Chan B; Titmuss E; Bohm A; Laskin J; Jones SJM; Pleasance E; Nelson J; Fok A; Lim H; Karsan A; Renouf DJ; Schrader KA; Sun S; Yip S; Schaeffer DF; Marra MA; Regier DA
Cancer Med; 2021 Aug; 10(15):5131-5140. PubMed ID: 34152087
[TBL] [Abstract] [Full Text] [Related]
16. Cost Effectiveness of Ribociclib in Combination with Fulvestrant for the treatment of Postmenopausal Women with HR+/HER2- Advanced breast cancer Who Have Received No or Only One Prior Line of Endocrine Therapy: A Canadian Healthcare Perspective.
Stellato D; Thabane ME; Park J; Chandiwana D; Delea TE
Pharmacoeconomics; 2021 Sep; 39(9):1045-1058. PubMed ID: 34105083
[TBL] [Abstract] [Full Text] [Related]
17. Automated NLP Extraction of Clinical Rationale for treatment Discontinuation in breast cancer.
Alkaitis MS; Agrawal MN; Riely GJ; Razavi P; Sontag D
JCO Clin Cancer Inform; 2021 May; 5():550-560. PubMed ID: 33989016
[TBL] [Abstract] [Full Text] [Related]
18. Predicting optimal treatment regimens for patients with HR+/HER2- breast cancer using machine learning based on electronic health records.
Cui ZL; Kadziola Z; Lipkovich I; Faries DE; Sheffield KM; Carter GC
J Comp Eff Res; 2021 Jun; 10(9):777-795. PubMed ID: 33980048
[No Abstract] [Full Text] [Related]
19. Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens.
Moy B; Oliveira M; Saura C; Gradishar W; Kim SB; Brufsky A; Hurvitz SA; Ryvo L; Fagnani D; Kalmadi S; Silverman P; Delaloge S; Alarcon J; Kwong A; Lee KS; Ang PCS; Ow SGW; Chu SC; Bryce R; Keyvanjah K; Bebchuk J; Zhang B; Oestreicher N; Bose R; Chan N
Breast Cancer Res Treat; 2021 Jul; 188(2):449-458. PubMed ID: 33909203
[TBL] [Abstract] [Full Text] [Related]
20. Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan.
Lin YJ; Kuo CN; Ko Y
Breast; 2021 Jun; 57():18-24. PubMed ID: 33706025
[TBL] [Abstract] [Full Text] [Related]
[Next]
